TY - JOUR
T1 - Vitamin B6 supplementation increases immune responses in critically ill patients
AU - Cheng, C. H.
AU - Chang, S. J.
AU - Lee, B. J.
AU - Lin, K. L.
AU - Huang, Y. C.
N1 - Funding Information:
Objective: To investigate whether vitamin B6 supplementation has a beneficial effect on immune responses in critically ill patients. Design: A single-blind intervention study. Setting: The study was performed at the Taichung Veterans General Hospital, the central part of Taiwan. Subjects: Fifty-one subjects who stayed over 14 days in the intensive care unit completed the study. Subjects were not treated with any vitamin supplement before the intervention. Interventions: Patients were randomly assigned to one of three groups, control (n = 20), a daily injection of 50 mg vitamin B-6 (B6-50, n = 15), or 100 mg vitamin B-6 (B6-100, n = 16) for 14 days. Main outcome measures: Plasma pyridoxal 5′-phosphate (PLP), pyridoxal (PL), 4-pyridoxic acid (4-PA), erythrocyte alanine (EALT-AC) and aspartate (EAST-AC) aminotransaminase activity coefficient, and urinary 4-PA were measured. The levels of serum albumin, hemoglobin, hematocrit, high-sensitivity C-reactive protein (hs-CRP) and immune responses (white blood cell, neutrophils, total lymphocytes count (TLC), T-(CD3) and B-(CD19) lymphocytes, T-helper (CD4) and suppressor (CD8) cells) were determined. Results: Plasma PLP, PL, 4-PA and urinary 4-PA concentrations significantly increased in two treated groups. T-lymphocyte and T-helper cell numbers and the percentage of T-suppressor cell significantly increased on day 14 in the B6-50 group. Total lymphocyte count, T-helper and T-suppressor cell numbers, the percentage of T-lymphocyte cells and T-suppressors significantly increased in the B6-100 group at the 14th day. There were no significant changes with respect to immune responses in the control group over 14 days. Conclusions: A large dose of vitamin B6 supplementation (50 or 100 mg/day) could compensate for the lack of responsiveness of plasma PLP to vitamin B6 intake, and further increase immune response of critically ill patients. Sponsorship: This study was supported by the National Science Council, Taiwan, Republic of China (NSC-92-2320-B-040-026).
PY - 2006/10
Y1 - 2006/10
N2 - Objective: To investigate whether vitamin B6 supplementation has a beneficial effect on immune responses in critically ill patients. Design: A single-blind intervention study. Setting: The study was performed at the Taichung Veterans General Hospital, the central part of Taiwan. Subjects: Fifty-one subjects who stayed over 14 days in the intensive care unit completed the study. Subjects were not treated with any vitamin supplement before the intervention. Interventions: Patients were randomly assigned to one of three groups, control (n=20), a daily injection of 50mg vitamin B-6 (B6-50, n=15), or 100mg vitamin B-6 (B6-100, n=16) for 14 days.Main outcome measures:Plasma pyridoxal 5′-phosphate (PLP), pyridoxal (PL), 4-pyridoxic acid (4-PA), erythrocyte alanine (EALT-AC) and aspartate (EAST-AC) aminotransaminase activity coefficient, and urinary 4-PA were measured. The levels of serum albumin, hemoglobin, hematocrit, high-sensitivity C-reactive protein (hs-CRP) and immune responses (white blood cell, neutrophils, total lymphocytes count (TLC), T- (CD3) and B-(CD19) lymphocytes, T-helper (CD4) and suppressor (CD8) cells) were determined. Results: Plasma PLP, PL, 4-PA and urinary 4-PA concentrations significantly increased in two treated groups. T-lymphocyte and T-helper cell numbers and the percentage of T-suppressor cell significantly increased on day 14 in the B6-50 group. Total lymphocyte count, T-helper and T-suppressor cell numbers, the percentage of T-lymphocyte cells and T-suppressors significantly increased in the B6-100 group at the 14th day. There were no significant changes with respect to immune responses in the control group over 14 days. Conclusions: A large dose of vitamin B6 supplementation (50 or 100mg/day) could compensate for the lack of responsiveness of plasma PLP to vitamin B6 intake, and further increase immune response of critically ill patients.
AB - Objective: To investigate whether vitamin B6 supplementation has a beneficial effect on immune responses in critically ill patients. Design: A single-blind intervention study. Setting: The study was performed at the Taichung Veterans General Hospital, the central part of Taiwan. Subjects: Fifty-one subjects who stayed over 14 days in the intensive care unit completed the study. Subjects were not treated with any vitamin supplement before the intervention. Interventions: Patients were randomly assigned to one of three groups, control (n=20), a daily injection of 50mg vitamin B-6 (B6-50, n=15), or 100mg vitamin B-6 (B6-100, n=16) for 14 days.Main outcome measures:Plasma pyridoxal 5′-phosphate (PLP), pyridoxal (PL), 4-pyridoxic acid (4-PA), erythrocyte alanine (EALT-AC) and aspartate (EAST-AC) aminotransaminase activity coefficient, and urinary 4-PA were measured. The levels of serum albumin, hemoglobin, hematocrit, high-sensitivity C-reactive protein (hs-CRP) and immune responses (white blood cell, neutrophils, total lymphocytes count (TLC), T- (CD3) and B-(CD19) lymphocytes, T-helper (CD4) and suppressor (CD8) cells) were determined. Results: Plasma PLP, PL, 4-PA and urinary 4-PA concentrations significantly increased in two treated groups. T-lymphocyte and T-helper cell numbers and the percentage of T-suppressor cell significantly increased on day 14 in the B6-50 group. Total lymphocyte count, T-helper and T-suppressor cell numbers, the percentage of T-lymphocyte cells and T-suppressors significantly increased in the B6-100 group at the 14th day. There were no significant changes with respect to immune responses in the control group over 14 days. Conclusions: A large dose of vitamin B6 supplementation (50 or 100mg/day) could compensate for the lack of responsiveness of plasma PLP to vitamin B6 intake, and further increase immune response of critically ill patients.
UR - http://www.scopus.com/inward/record.url?scp=33749353824&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749353824&partnerID=8YFLogxK
U2 - 10.1038/sj.ejcn.1602439
DO - 10.1038/sj.ejcn.1602439
M3 - Article
C2 - 16670691
AN - SCOPUS:33749353824
SN - 0954-3007
VL - 60
SP - 1207
EP - 1213
JO - European Journal of Clinical Nutrition
JF - European Journal of Clinical Nutrition
IS - 10
ER -